• Initiator Pharma secured two new European patents for pudafensine, covering pain treatment and an immediate-release oral formulation.
• The EPO granted the patents on Aug. 19, 2026, adding to a female sexual dysfunction patent issued in February 2026.
• The pain patent (EP 4 608 400) runs to 2043, supports a low-dose regimen, ties to a Phase 2a vulvodynia study.
• The formulation patent (EP 4 731 189) runs to 2044, covers a pellet-based immediate-release oral dosage form for once-daily use.
• Management expects topline Phase 2a vulvodynia data by end-2026, keeping the lead program on track.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Initiator Pharma A/S published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.